James P. Dean, MD, PhD

Executive Medical Director Oncology
AbbVie Inc.

Poster(s):

• 1414 - Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia /small lymphocytic lymphoma in the phase 2 CAPTIVATE study